

February 1, 2025

BSE Limited
Department of Corporate Services
Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai 400 001
Scrip Code No: 542665

National Stock Exchange of India Limited
Listing Department, Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051
Company Symbol: NEOGEN

Sub: Outcome of Board Meeting held on Saturday, February 1, 2025.

Ref.: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 33 and Regulation 30 read with Schedule III of the Listing Regulations, we wish to inform you that the Board of Directors of Neogen Chemicals Limited (“**the Company**”) had at its meeting held today i.e., Saturday, February 1, 2025, at 2:30 p.m. and concluded at 7:30 p.m., inter alia considered and approved the following:

1. Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter and nine months ended December 31, 2024, pursuant to Regulation 33 of the Listing Regulations along with the “Limited Review Report” thereon as provided by the Statutory Auditors of the Company, which has been duly reviewed and recommended by the Audit Committee and the same is enclosed herewith as **Annexure 1**. This intimation shall also be considered for Integrated Filing (Financial) for the quarter and nine-months ended December 31, 2024 pursuant to the SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025.
 - A. Financial Results – Enclosed
 - B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. – Not Applicable
 - C. Disclosure of outstanding default on loans and debt securities- Not Applicable
 - D. Format for disclosure of related party transactions – Not Applicable
 - E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (standalone and consolidated separately) – Not Applicable

The above information is also being uploaded on the Company’s website at <https://neogenchem.com/financial-performance/>.

Kindly take the above information on your records.

Yours faithfully,
For **Neogen Chemicals Limited**

Unnati Kanani
Company Secretary & Compliance Officer
Membership No: ACS 35131
Place: Thane
Encl.: A/a



FoF 2, Phoenix House, 'B' Wing,
4th Floor, 462, Senapati Bapat Marg,
Lower Parel,
Mumbai-400 013.
India


Phone : +91 22 4619 7023/24/25
: +91 22 4606 7023
Email : mail@cnj.in
Web : www.cnj.in

Independent Auditors' Limited Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
Neogen Chemicals Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Neogen Chemicals Limited ("the Company") for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standards on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in Paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Chandabhoy & Jassoobhoy

Chartered Accountants

5. We draw your attention to Note 2 and 3 to the Statement in respect of Scheme of Amalgamation of Buli Chemicals India Private Limited, the wholly owned subsidiary with the Company with effect from the appointed date of April 1, 2024 as approved by the Hon'ble National Company Law Tribunal, (Mumbai Bench) vide their order dated January 9, 2025. This Scheme, being a common control transaction has been accounted for based on the pooling of interest method in the Statement in accordance with the accounting treatment specified in the Scheme, i.e. as prescribed in 'Appendix C' of Ind AS 103- "Business Combinations". Accordingly, figures included in these financial results in respect of prior periods i.e. for the quarter and nine months ended December 31, 2023, year ended March 31, 2024 and quarter ended September 30, 2024, have been restated as if the business combination had occurred with effect from the beginning of the previous year i.e. April 1, 2023. Our conclusion is not modified in respect of this matter.

6. Other Matters

a. The statement includes comparative figures of the Company for quarter and nine months ended December 31, 2023 which have been restated as mentioned in para 5 above based on the figures of the said periods which have been reviewed by the predecessor firm of statutory auditors vide their report dated February 9, 2024 in which the predecessor auditor have expressed unmodified conclusion. The statement also includes figures of the Company for the year ended March 31, 2024 which have been restated as mentioned in para 5 above based on the figures of the said periods which have been audited by the predecessor firm of statutory auditors vide their report dated April 30, 2024 in which the predecessor auditor have expressed unmodified opinion.

Our conclusion on the Statement is not modified in respect of these matter.

b. We did not review the financial information of Buli Chemicals India Private Limited' the wholly owned subsidiary of the Company (now amalgamated with the Company) ('amalgamated subsidiary') for the quarter and nine months ended December 31, 2024 whose financial results have been included in these standalone financial results of the Company in view of the Scheme of Amalgamation approved by the Hon'ble National Company Law Tribunal vide their order dated January 9, 2025 with effect from the appointed date of April 1, 2024. The financial results of the said amalgamated subsidiary reflect total revenue of Rs 25.58 crore and Rs.60.36 crore, total profit after tax of Rs 2.73 crore and Rs.6.08 crore and total comprehensive profit of Rs 2.75 crore and Rs. 6.13 crore for the quarter and nine months ended December 31, 2024 respectively as considered in the Statement. The financial results of the said amalgamated subsidiary have been reviewed by the other auditor whose report has been furnished to us by the Management, and our conclusion in so far as it relates to amounts and disclosures included in respect of the said amalgamated subsidiary, is based solely on the report of other auditor and procedure performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matter.

For **Chandabhoy & Jassoobhoy**
Chartered Accountants
Firm Registration No. 101647W



Bhupendra T. Nagda
Partner

Membership No.: 102580
UDIN: 25102580BMN4YJ2450



Mumbai: February 1, 2025



NEOGEN CHEMICALS LIMITED.
(CIN : L24200MH1989PLC050919)

Statement of Standalone Unaudited Financial Results for the Quarter and Nine months ended December 31, 2024

Sr. No.	Particulars	Standalone					(Rs. in Cr)
		For the Quarter Ended			For the Nine months ended		For the Year Ended
		31 Dec 2024 Unaudited	30 Sep 2024 ^ Unaudited	31 Dec 2023 ^ Unaudited	31 Dec 2024 Unaudited	31 Dec 2023 ^ Unaudited	31 Mar 2024 ^ Audited
I	Income						
	(a) Revenue from operations	200.41	193.14	164.47	569.90	491.12	701.42
	(b) Other income	2.05	2.24	1.50	7.10	5.26	8.08
	Total Income (net)	202.46	195.38	165.97	577.00	496.38	709.50
II	Expenses						
	(a) Cost of materials consumed	152.98	89.03	119.76	340.21	337.77	487.22
	(b) Changes in inventories of finished goods, work-in progress and stock-in-trade	(44.30)	21.44	(28.49)	(26.33)	(67.02)	(92.10)
	(c) Employee benefits expense	14.17	13.66	15.12	42.16	44.65	57.32
	(d) Finance costs	13.07	12.30	10.52	34.88	32.36	42.00
	(e) Depreciation and Amortization Expense	6.58	6.61	5.74	19.58	17.01	22.82
	(f) Other Expenses	39.91	32.52	36.16	107.90	97.50	132.78
	Total Expenses	182.41	175.56	158.81	518.40	462.27	650.04
III	Profit/(loss) before taxes (I-II)	20.05	19.82	7.16	58.60	34.11	59.46
IV	Income Tax						
	1. Current Tax	4.88	4.14	3.19	12.64	8.21	12.25
	2. Tax Adjustment relating to earlier period	0.46	-	-	0.46	-	-
	3. Deferred Tax	0.30	0.82	1.72	2.29	4.02	6.08
V	Profit for the period (III-IV)	14.41	14.86	2.25	43.21	21.88	41.13
VI	Other comprehensive income						
	i) Items that will not be reclassified to profit or loss	(0.15)	(0.12)	(0.27)	(0.47)	(0.07)	(0.80)
	(ii) Income tax related to items that will not be reclassified to profit or loss	0.04	0.02	0.08	0.12	0.02	0.20
	Total Other comprehensive (expense)/ income, net of tax	(0.11)	(0.10)	(0.19)	(0.35)	(0.05)	(0.60)
VII	Total comprehensive income for the period (V + VI)	14.30	14.76	2.06	42.86	21.83	40.53
VIII	Paid up equity Share Capital (Face Value per share of Rs. 10/- each)	26.38	26.38	26.38	26.38	26.38	26.38
IX	Other Equity	-	-	-	-	-	739.73
X	Earnings Per Share (amount in Rs.) Basic & Diluted (*Not Annualized)	5.46*	5.63*	0.87*	16.38*	8.66*	16.10


For and on behalf of Board of Directors



[Signature]

Dr. Harin Kanani
Managing Director
DIN : 05136947

Place : Thane , India
Date : 1st February 2025



Notes :

1. The above unaudited financial results of the Company for the quarter and nine months ended December 31, 2024 have been prepared in accordance with the IND AS, as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 and the other accounting principles generally accepted in India and were reviewed by the Statutory Auditor and recommended by the Audit Committee in its meeting held on February 1, 2025 and was approved by the Board of Directors at their meeting held on February 1, 2025.
2. ^The Hon'ble National Company Law Tribunal, Mumbai Bench ("Hon'ble NCLT") has on January 9, 2025, pronounced the order sanctioning and approving the said Scheme of Amalgamation of Buli Chemicals India Private Limited i.e. wholly owned subsidiary ("Transferor Company/BULI") with Neogen Chemical Limited i.e. holding company ("Transferee Company/ NCL/ the Company") and their respective shareholders ("Scheme"), under sections 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules framed thereunder ("Act") ("Order") with appointed date as April 1, 2024. The Scheme is effective from the date of filing of the certified copy of Order with the Registrar of Companies, Mumbai by both the Transferor Company and Transferee Company i.e. January 31, 2025. The Transferee Company has intimated the Stock Exchange about the Effective Date of the Scheme on January 31, 2025 ("Effective Date").
3. The Scheme sanctioned by Hon'ble NCLT, being a common control transaction has been accounted for based on the pooling of interests method retrospectively for all periods presented in the standalone results in accordance with Appendix C to Ind AS 103 - "Business Combinations".

Accordingly, the financial information included in these financial results in respect of prior periods has been restated as if the business combination had occurred with effect from the beginning of the previous year i.e., April 1, 2023. The effect of mergers on the amounts of Revenue, Expense, Profit, Total Comprehensive Income and Reserves published in the respective period are as shown in the below table:

(Rs. In crores)

Particulars	Quarter Ended		Nine Months ended	Year ended
	30/09/2024	31/12/2023		
			31/12/2023	31/03/2024
Total Income				
As published in respective period	176.57	168.85	510.92	705.14
As restated for the effect of the merger(s)	195.38	165.97	496.38	709.50
Total Expenses				
As published in respective period	159.12	156.63	470.51	641.50
As restated for the effect of the merger(s)	175.56	158.81	462.27	650.04
Profit before tax:				
As published in respective period	17.45	12.22	40.41	63.64
As restated for the effect of the merger(s)	19.82	7.16	34.11	59.46
Profit after tax:				
As published in respective period	13.03	5.80	26.36	44.06
As restated for the effect of the merger(s)	14.86	2.25	21.88	41.13
Total Other comprehensive Income				
As published in respective period	(0.15)	(0.19)	(0.05)	(0.55)
As restated for the effect of the merger(s)	(0.10)	(0.19)	(0.05)	(0.60)
Total Comprehensive Income:				
As published in respective period	12.88	5.61	26.31	43.51
As restated for the effect of the merger(s)	14.76	2.06	21.82	40.53
Reserves:				
As published in respective period	-	-	-	739.04
As restated for the effect of the merger(s)	-	-	-	739.73



4. Previous period / year's figures have been regrouped/rearranged wherever necessary to make them comparable.
5. The company is in the business of manufacturing specialty chemicals and accordingly has one reportable business segment.
6. For more details on results, visit investor relations section of the Company's website at <https://neogenchem.com/financial-performance/> and financial result under corporates section of Stock Exchange's website at www.nseindia.com and www.bseindia.com.

For and on behalf of the Board of Directors of
Neogen Chemicals Limited

Place : Thane , India
Date : February 1 ,2025



A handwritten signature in blue ink, appearing to read "Harin Kanani".

Dr. Harin Kanani
Managing Director
DIN : 05136947





FoF 2, Phoenix House, 'B' Wing,
4th Floor, 462, Senapati Bapat Marg,
Lower Parel,
Mumbai-400 013.
India

Phone : +91 22 4619 7023/24/25

: +91 22 4606 7023

Email : mail@cnj.in


Web : www.cnj.in

Independent Auditors' Limited Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Neogen Chemicals Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Neogen Chemicals Limited ("the Parent") and its two subsidiaries and one joint venture (the Parent and its subsidiaries and joint venture together referred to as "the Group") for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standards on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



Chandabhoy & Jassoobhoy

Chartered Accountants

4. Based on our review conducted and procedures performed as stated in Paragraph 3 above and based on the consideration of the review report of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw your attention to Note 2 to the Statement in respect of Scheme of Amalgamation of Bull Chemicals India Private Limited, the wholly owned subsidiary with the Company with effect from the appointed date of April 1, 2024 as approved by the Hon'ble National Company Law Tribunal, (Mumbai Bench) vide their order dated January 9, 2025. The Scheme is effective from the date of filing of the certified copy of Order with the Registrar of Companies, Mumbai by both the Transferor Company and Transferee Company i.e. January 31, 2025. Our conclusion is not modified in respect of this matter.
6. The Statement includes the results of the following entities:

Sr. no.	Name of the Entity	Relationship
1.	Neogen Chemicals Limited	Parent
2.	Neogen Ionics Limited	Subsidiary
3.	Neogen Chemicals Japan Corporation Limited	Subsidiary
4.	Dhara Fine Chem Industries (Registered Partnership Firm)	Joint Venture

7. Other Matters

- a. The statement includes comparative figures of the Company for quarter and nine months ended December 31, 2023 which have been reviewed by the predecessor firm of statutory auditors vide their report dated February 9, 2024 in which the predecessor auditor have expressed unmodified conclusion. The statement also includes figures of the Company for the year ended March 31, 2024 which have been audited by the predecessor firm of statutory auditors vide their report dated April 30, 2024 in which the predecessor auditor have expressed unmodified opinion.
Our conclusion on the Statement is not modified in respect of these matter.
- b. We did not review the financial results of the one subsidiary included in the statement whose financial information reflects total revenues of Rs.3.62 crores and Rs. 11.25 crores, total net Profit/(loss) after tax of Rs. (3.38) crore and Rs.(7.98) crore and total comprehensive income/(expense) of Rs.(3.39) crore and Rs. (7.96) crore for the quarter and year-to-date period ended on 31 December 2024 respectively, as considered in the statement. These financial results have been reviewed by other auditor whose review report has been furnished to us by the management and our conclusion in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.
Our conclusion on the Statement is not modified in respect of this matter.



Chandabhoy & Jassoobhoy
Chartered Accountants

- c. The Statement includes the interim financial information/ financial results of one subsidiary which have not been reviewed, whose interim financial information/ financial results reflects total revenues of Rs. Nil crore and Rs. Nil crore, total net profit after tax of Rs. Nil crore and Rs. Nil crore and total comprehensive income of Rs. Nil crore and Rs. Nil crore, for the quarter and year-to-date period ended on 31 December 2024 respectively, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of Rs. 0.08 crore and Rs. 0.15 crore and total comprehensive income of Rs. 0.08 crore and Rs. 0.15 crore, for the quarter and year-to-date period ended 31 December 2024 respectively, as considered in the Statement, in respect of 1 associate, based on their interim financial information/ financial results which have not been reviewed. According to the information and explanations given to us by the management, these interim financial information/ financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of this matter.
- d. We did not review the financial information of Buli Chemicals India Private Limited' the wholly owned subsidiary of the Company (now amalgamated with the Company) ('amalgamated subsidiary') for the quarter and nine months ended December 31, 2024 whose financial results have been included in these consolidated financial results of the Company in view of the Scheme of Amalgamation approved by the Hon'ble National Company Law Tribunal vide their order dated January 9, 2025 with effect from the appointed date of April 1, 2024. The financial results of the said amalgamated subsidiary reflect total revenue of Rs 25.58 crore and Rs.60.36 crore, total profit after tax of Rs 2.73 crore and Rs.6.08 crore and total comprehensive profit of Rs 2.75 crore and Rs. 6.13 crore for the quarter and nine months ended December 31, 2024 respectively as considered in the Statement. The financial results of the said amalgamated subsidiary have been reviewed by the other auditor whose report has been furnished to us by the Management, and our conclusion in so far as it relates to amounts and disclosures included in respect of the said amalgamated subsidiary, is based solely on the report of other auditor and procedure performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of these matter.

For **Chandabhoy & Jassoobhoy**
Chartered Accountants
Firm Registration No. 101647W



Bhupendra T. Nagda
Partner

Membership No.: 102580

UDIN: 25102580BMNYYK8155



Mumbai: February 1, 2025



NEOGEN CHEMICALS LIMITED.
(CIN : L24200MH1989PLC050919)

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine months ended December 31, 2024


Sr. No.	Particulars	Consolidated						(Rs. in Cr)
		For the Quarter Ended			For the Nine months ended		For the Year Ended	
		31 Dec 2024	30 Sep 2024	31 Dec 2023	31 Dec 2024	31 Dec 2023	31 Mar 2024	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Income							
	(a) Revenue from operations	201.43	193.36	164.44	574.74	491.02	690.67	
	(b) Other income	1.06	0.79	1.58	3.42	5.26	7.47	
	Total Income (net)	202.49	194.15	166.02	578.16	496.28	698.14	
II	Expenses							
	(a) Cost of materials consumed	151.51	88.62	119.47	341.91	337.43	474.59	
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(42.17)	21.21	(28.49)	(26.35)	(67.02)	(92.10)	
	(c) Employee benefits expense	15.69	14.83	16.73	46.53	47.24	62.00	
	(d) Finance costs	13.43	12.75	10.52	36.00	32.37	42.06	
	(e) Depreciation and Amortization Expense	7.10	7.12	5.74	21.03	17.01	22.87	
	(f) Other Expenses	41.76	34.19	36.44	112.71	99.11	136.13	
	Total Expenses	187.32	178.72	160.41	531.83	466.14	645.55	
III	Share of Profit	0.08	0.05	0.09	0.15	0.16	0.18	
IV	Profit/(loss) before taxes (I - II + III)	15.25	15.48	5.70	46.48	30.30	52.77	
V	Income Tax							
	1. Current Tax	4.99	4.17	3.19	12.80	8.21	12.24	
	2. Tax Adjustment relating to earlier period	0.46	-	-	0.46	-	-	
	3. Deferred Tax	(0.21)	0.35	1.45	0.80	3.37	4.88	
VI	Profit for the period (IV-V)	10.01	10.96	1.06	32.42	18.72	35.65	
VII	Other comprehensive income							
	i) Items that will not be reclassified to profit or loss	(0.16)	(0.13)	(0.27)	(0.47)	(0.07)	(0.80)	
	(ii) Income tax related to items that will not be reclassified to profit or loss	0.04	0.03	0.07	0.12	0.02	0.20	
	Total Other comprehensive (expense)/income, net of tax	(0.12)	(0.10)	(0.20)	(0.35)	(0.05)	(0.60)	
VIII	Total comprehensive income for the period (VI+VII)	9.89	10.86	0.86	32.07	18.67	35.05	
IX	Paid up equity Share Capital (Face Value per share of Rs. 10 each)	26.38	26.38	26.38	26.38	26.38	26.38	
X	Other Equity						733.91	
	Earning Per Equity Share (amount in Rs.) Basic & Diluted (*Not Annualized)	3.80*	4.15*	0.41*	12.29*	7.41*	13.96	

For and on behalf of Board of Directors

Place: Thane, India
Date : 1st February 2025



Dr. Harin Kanani
Managing Director
DIN : 05136947



Notes :

1. The above unaudited financial results of the Company for the quarter and nine months ended December 31 , 2024 have been prepared in accordance with the IND AS, as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 and the other accounting principles generally accepted in India and were reviewed by the Statutory Auditor and recommended by the Audit Committee in its meeting held on February 1, 2025 and was approved by the Board of Directors at their meeting held on February 1, 2025.
2. The Hon'ble National Company Law Tribunal, Mumbai Bench ("Hon'ble NCLT") has on January 9, 2025, pronounced the order sanctioning and approving the said Scheme of Amalgamation of Buli Chemicals India Private Limited i.e. wholly owned subsidiary ("Transferor Company/BULI") with Neogen Chemical Limited i.e. holding company ("Transferee Company/ NCL/ the Company") and their respective shareholders ("Scheme"), under sections 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules framed thereunder("Act") -("Order") with appointed date as April 1, 2024. The Scheme is effective from the date of filing of the certified copy of Order with the Registrar of Companies, Mumbai by both the Transferor Company and Transferee Company i.e. January 31, 2025. The Transferee Company has intimated the Stock Exchange about the Effective Date of the Scheme on January 31,2025.
3. The unaudited financial results of Dhara Fine chem Industries (a joint venture where the Company is holding 90% of the capital contribution), the wholly owned subsidiaries of the Company namely Neogen Ionics Limited and Neogen Chemicals Japan Corporation Limited for the quarter and nine months ended December 31, 2024 are considered for Unaudited Consolidated Financial Results.
4. Previous period / year's figures have been regrouped/rearranged wherever necessary to make them comparable.
5. The Group is in the business of manufacturing chemicals and accordingly has one reportable business segment.
6. For more details on results, visit investor relations section of the Company's website at <https://neogenchem.com/financial-performance/> and financial result under corporates section of Stock Exchange's website at www.nseindia.com and www.bseindia.com.

For and on behalf of the Board of Directors of
Neogen Chemicals Limited



Dr. Harin Kanani
Managing Director
DIN : 05136947

Place : Thane , India
Date : February 1 ,2025

